Disease Cell-targeted Precision Medicine

Ashvattha Therapeutics are harnessing the power of Hydroxyl Dendrimers (HDs) to create a new class of Disease Cell-targeted Precision Medicine

Welcome to Ashvattha

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel hydroxyl dendrimer (HD) therapeutics (HDTs) to treat unmet medical needs in oncology, ophthalmology, and inflammatory diseases. We believe that HDTs will become the future of targeted therapeutics and unlock new levels of patient care.

We are developing HD radiotherapeutics leveraging our ability to target tumor associated macrophages (TAMs)

Our solution enables patient selection followed by treatment with anti-neuroinflammatory agent coupled to HDT to target reactive microglia

We have designed and optimized an HDT that precisely targets reactive macrophages and retinal pigment epithelial cells (RPEs) after systemic administration

OP-101 selectively targets pro-inflammatory macrophages and microglia responsible for excessive cytokine production in severe COVID-19 patients

Latest News

Neurologists test novel compound for lung and brain injury in severe COVID-19 patients (UT Health News)

Neurologists are researching whether a novel immunomodulatory treatment, OP-101, an investigational compound developed by Ashvattha Therapeutics, can dampen lung and brain injury in hospitalized COVID-19 patients through a clinical trial at The University of Texas Health Science Center at Houston.

Ashvattha Therapeutics Announces Positive Interim Data from Ongoing Phase 2 PRANA Clinical Study of OP-101 in Severe COVID-19 Patients

Ashvattha announced positive interim results from its ongoing multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hyperinflammation in hospitalized adults with severe COVID-19.

Ashvattha Therapeutics to Present at 2021 Sachs 7th Annual Digital Immuno-Oncology Innovation Forum

Ashvattha will present at the Sachs 7th Annual Immuno-Oncology Innovation Forum, held virtually on May 18-20

Ashvattha Therapeutics Presents Transformative Anti-Angiogenesis Treatment for Retinal Disorders at ARVO 2021

Ashvattha announced the presentation of a virtual poster supporting the development of its proprietary HDT, D-4517, for treatment of AMD at the 2021 ARVO Annual Meeting.

Ashvattha Therapeutics Announces Collaboration with Stanford University for Preclinical Development of a Novel Neuroimaging Agent, OP-801

Ashvattha initiates a preclinical proof of concept study for OP-801 imaging of neuroinflammation. This Investigational New Drug (IND)-enabling research will be conducted in collaboration with a team of researchers at the Stanford University School of Medicine led by Michelle James, Ph.D., Assistant Professor of Radiology and Neurology.